Merck delivered a remarkable financial execution in the third quarter which is expected to continue in the upcoming result. The investments that the management is making in their strong pipeline and portfolio, as well as in business development providing critical advances and long-term value to patients and shareholders. The increasing popularity of their Molnupiravir medication against Covid-19 across the globe has been an important growth driver. The management has also continued to implement ....
